Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile

PURPOSE: Dabigatran etexilate is an oral, reversible, direct thrombin inhibitor licensed for the prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. The aim of this study was to investigate whether, and to what extent, a switch from enoxparin to dabigatra...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemens, Andreas, van Ryn, Joanne, Sennewald, Regina, Yamamura, Norio, Stangier, Joachim, Feuring, Martin, Härtter, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332339/
https://www.ncbi.nlm.nih.gov/pubmed/22252796
http://dx.doi.org/10.1007/s00228-011-1205-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332339/
https://www.ncbi.nlm.nih.gov/pubmed/22252796
http://dx.doi.org/10.1007/s00228-011-1205-2

Ejemplares similares